Pharmaceutical company Amylin Pharmaceuticals, who sell diabetes drug Byetta, are going to let around 200 jobs go. The redundancies comprise approximately a third of the sales force of the company .
Alongside Eli Lilly, Amylin are developing a once-per-week version of diabetes drug Byetta. The aim of the restructuring is to strengthen the sales efficiency and the partnership with Lilly.
Amylin are thought to be seeking a final sales team of 325 representatives. The team will focus on doctors and endocrinologists who treat large number of people with diabetes .
The diabetes company, who largely specialise in drug for people with type 2 diabetes, will aim to save millions through the changes in the next few years.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…